Steven Zeig, MD
Nephrology · Hollywood, FLNPI 1982693719
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,352 of the $32,606 with a category attached, or 77.8%. 25 manufacturers reported payments, led by Amgen at 44.7% of the total. Reporting peaked in 2022 at $13,267 and has fallen 97.7% since, to $311 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $207.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- Vifor Pharma, Inc.$14K
- CSL Behring$1K
- Mallinckrodt Hospital Products Inc.$863
- Travere Therapeutics, Inc.$290
- Novo Nordisk$221
- plus $988 from 19 others
Across 586 payments — averaging $24,331 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$10.9M
- CSL Behring$926K
- Eli Lilly$584K
- Astrazeneca UK Limited$531K
- Amgen$446K
- GSK$220K
- plus $648K from 19 others
What the payments were for
- Consulting fees$6002%
- Speaking & faculty fees$25,35278%
- Travel & lodging$2,6278%
- Food & beverage$4,01912%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 25 | $14,566 |
| Vifor Pharma, Inc. | 24 | $14,311 |
| CSL Behring | 7 | $1,369 |
| Mallinckrodt Hospital Products Inc. | 34 | $863 |
| Travere Therapeutics, Inc. | 5 | $290 |
| Novo Nordisk | 6 | $221 |
| Bayer | 7 | $148 |
| Pfizer | 9 | $141 |
| AstraZeneca | 7 | $135 |
| Johnson & Johnson | 6 | $94 |
| Boston Scientific | 4 | $74 |
| Abbott | 3 | $67 |
| Amarin Pharma, Inc. | 3 | $49 |
| Merck | 3 | $45 |
| Boehringer Ingelheim | 2 | $37 |
| Novartis | 2 | $30 |
| Lilly USA, LLC | 2 | $29 |
| GSK | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,606 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $35,391 |
| TradjentaLinagliptin | 22 | $32,491 |
| EliquisApixaban | 30 | $27,198 |
| ProcritEpoetin Alfa | 12 | $24,995 |
| AuryxiaFerric Citrate | 11 | $22,429 |
| EntrestoSacubitril/Valsartan | 16 | $14,177 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $9,210 |
| JardianceEmpagliflozin | 11 | $6,616 |
| TrulancePlecanatide | 12 | $6,591 |
| Fentanyl | 37 | $5,845 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 162 | $3,725 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $1,216 |
| Sevelamer Carbonate | 16 | $1,139 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $1,132 |
| Nifedipine ErNifedipine | 24 | $1,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $37 | $39,10733 claims |
| Lilly USA, LLCMounjaro | $29 | $35,39135 claims |
| PfizerEliquis | $141 | $27,19830 claims |
| Johnson & JohnsonProcrit | $94 | $24,99512 claims |
| NovartisEntresto | $30 | $14,17716 claims |
| AstraZenecaLokelma | $135 | $9,21013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Hollywood
- Julio VijilHollywood$29K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.